Kangzhe Pharmaceutical announced that the innovative drug complement factor B inhibitor CMS-D017 capsules independently developed by the company obtained a drug clinical trial approval notice issued by the China National Drug Administration on July 15, 2026, and agreed to carry out clinical trials to treat age-related macular degeneration indications. Previously, CMS-D017 had obtained clinical trial approval notices for paroxysmal nocturnal hemoglobinuria and renal disease indications mediated by complement participation on January 30 and February 3, 2026, respectively.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.